Daewoong Co (003090.KS) Stock Price

Daewoong Co Price

KOSPI·CLOSED
16,000.00
​
Market closed

Revenue has compounded at 7.7% per year over the past 19 years to 2.07 T KRW. Earnings per share have grown at 11.0% per year over the last 19 years. Daewoong Co's net margin stands at 8.5%, up from 5.2% several years earlier. Daewoong Co currently offers a dividend yield of about 1.25%. The payout ratio is around 5% of earnings. The dividend has grown at 5.1% per year over the past 19 years. Analysts set a median price target of 28,560.00 KRW, implying 78.5% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.

Daewoong Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Daewoong Co business model & stock analysis

Daewoong Co., Ltd. generates revenue through its subsidiaries, each specializing in distinct sectors. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, and Hanall Biopharma Co Ltd manufacture and sell pharmaceuticals, targeting healthcare providers and consumers seeking medical treatments. Daewoong Development Co Ltd operates in real estate rental and supply, serving commercial and residential tenants. IDS&Trust Co Ltd produces communication-related devices for technology markets, while Daewoong Life Science Co Ltd focuses on food processing and sales for retail and food service segments. Pampaeg Co Ltd handles packaging for quasi-drugs, catering to pharmaceutical and wellness product distributors. Daewoong Management Development Institute Co Ltd provides management and industrial training services to corporate clients. The company's revenue streams are diversified across pharmaceutical manufacturing, real estate services, communication devices, food processing, quasi-drug packaging, and corporate training. Pharmaceutical subsidiaries dominate the revenue mix, serving both institutional and consumer markets. Real estate operations contribute through long-term rental agreements, while communication device sales target technology-focused businesses. Food processing and quasi-drug packaging align with health and wellness industry demands, and training services support corporate workforce development. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, and Hanall Biopharma Co Ltd are key revenue drivers in the pharmaceutical sector, selling directly to hospitals, pharmacies, and consumers. Daewoong Development Co Ltd leases properties to businesses and individuals, generating steady rental income. IDS&Trust Co Ltd supplies communication devices to tech companies and service providers. Daewoong Life Science Co Ltd distributes processed food products through retail channels, and Pampaeg Co Ltd packages quasi-drugs for pharmaceutical firms. Training services from Daewoong Management Development Institute Co Ltd are contracted by corporations for employee development programs.

Frequently asked questions about Daewoong Co

Analysts currently set an average price target of 28,560.00 KRW for the Daewoong Co stock (median: 28,560.00 KRW), implying +78.5 % versus the latest price. The consensus is based on 5 analyst ratings.

5 analysts currently rate the Daewoong Co stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Daewoong Co to generate revenue of 2.42 T KRW and earnings per share of 3,693.05 KRW.

Converted at the current exchange rate, the Daewoong Co share trades at 10.64 EUR (16,000.00 KRW).

The Daewoong Co share (003090.KS) is listed on 1 stock exchanges, including: KOSPI (Seoul) (003090.KS).

The expected revenue of Daewoong Co is 2.42 T KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Daewoong Co is 159.48 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Daewoong Co is currently 4.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Daewoong Co stock.

The price-to-sales ratio (P/S) of Daewoong Co is currently 0.29. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Daewoong Co stock.

The Eulerpool Quality Score for Daewoong Co is 8/10.

The ISIN of Daewoong Co is KR7003090008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Daewoong Co is 003090.KS. The ticker symbol is used to trade Daewoong Co shares on the stock exchange.

Fair ValueTerminal
13,120.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Jun 26, 1973
ISIN
KR7003090008
Cusip
Y19152100
Market capitalization
654.46 B KRWMega Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
4.10
P/Ee 2027
3.55
P/Ee 2028
—
P/Ee 2029
—
P/S
P/Se
0.29
EV/EBIT
2.66
P/B Ratio
0.56
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
10.14 %
Dividend
Dividend yield
1.25 %
Est. Dividend Yield
3.00 %
Payout Ratio
4.93 %
Dividend growth Ø5Y
14.87 %
Dividend payments per year
1
Dividend paid since
27 years
Dividend not reduced since
12 years
Dividend increased since
0 years
Dividend withholding tax
22.00 %
Last updated Nov 4, 2026, 2:59 AM

Daewoong Co Peer Group

Daewoong Co Ticker

KOSPI · 003090.KS

Daewoong Co FIGI

003090:KS · BBG000BDGQY6003090:KP · BBG000BDGRG4